
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. has demonstrated a significant increase in the projected enterprise value, rising from $627 million to $959 million, which reflects the growing confidence in its therapeutic pipeline and strategic partnerships, including the collaboration with Novartis on luxdegalutamide (ARV-766). The enhanced valuations of key product candidates such as ARV-102 and ARV-806 further underscore the company’s solid position in the biotechnology sector, with respective valuations increasing to $247 million and $63 million. The overall positive adjustments in valuations are indicative of Arvinas's potential for continued financial growth and market impact, particularly as these products progress through their clinical development stages.
Bears say
Arvinas Inc. faces a negative outlook primarily due to reduced projections regarding potential revenue generation and market penetration for its therapies, notably with the peak revenue estimate for vepdegestrant being downgraded significantly from $641.2 million to $296.9 million by 2035. Additionally, the company exhibits challenges in maintaining its competitive positioning in the oncology field, particularly as its ORR in pancreatic ductal adenocarcinoma (PDAC) patients is anticipated to decline compared to other therapeutic options, indicating possible market share loss and diminished growth prospects. Furthermore, concerns regarding access to capital may impede the company's critical operations and delay paths to profitability, which further exacerbates the overall financial uncertainty surrounding its stock performance.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares